Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort
- DOI
- 10.5167/uzh-64660
- Published
- 2012
- Container
- Not recorded
- Publisher
- Lippincott Wiliams & Wilkins
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.5167/uzh-64660,
title = {Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort},
author = {Kallweit, U and Jelcic, I and Braun, N and Fischer, H and Zörner, B and Schreiner, B and Sokolov, A A and Martin, R and Weller, M and Linnebank, M},
year = {2012},
doi = {10.5167/uzh-64660},
url = {https://doi.org/10.5167/uzh-64660}
}RIS
TY - JOUR TI - Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort AU - Kallweit, U AU - Jelcic, I AU - Braun, N AU - Fischer, H AU - Zörner, B AU - Schreiner, B AU - Sokolov, A A AU - Martin, R AU - Weller, M AU - Linnebank, M PY - 2012 DO - 10.5167/uzh-64660 UR - https://doi.org/10.5167/uzh-64660 ER -
APA
U, K., I, J., N, B., H, F., B, Z., B, S., A, S. A., R, M., M, W., & M, L. (2012). Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. https://doi.org/10.5167/uzh-64660
Source records
- datacite · retrieved 2026-09-25T01:54:48.989Z